The Influences of Perfluoroalkyl Substances on the Rheumatoid Arthritis Clinic

Yun Zhao

Zhejiang University School of Medicine Second Affiliated Hospital

Hangbiao Jin

Zhejiang University of Technology

Jianli Qu

Zhejiang University of Technology

Sunzhao Zhang

Zhejiang University School of Medicine Second Affiliated Hospital

Shilei Hu

Zhejiang University of Technology

Jing Xue

Zhejiang University School of Medicine Second Affiliated Hospital

Meirong Zhao (✉ zhaomr@zjut.edu.cn)

Zhejiang University of Technology

Research Article

Keywords: rheumatoid arthritis, perfluoroalkyl substances, DAS28, environmental factor, visceral lesions

Posted Date: December 28th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-1189025/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Objective. Perfluoroalkyl substances (PFASs) are a class of synthetic organic fluorine chemicals, which have been mass-produced and widely used in the past 60 years, and also have been shown to be one of the major pollutants affecting human health. The impact of fluoride on the development of RA is unclear. The objective of this study was to assess the relationship between perfluoroalkyl substances and the clinic of RA.

Methods. A cohort of 155 patients with RA in Second Affiliated Hospital of Zhejiang University School of Medicine were investigated. Demographic and clinical data of these patients were recorded. The concentration of perfluoroalkyl substances were measured by ultra-performance liquid chromatography system (ACQUITY, UPLC) coupled to a tandem mass spectrometer that operated in negative ionization mode. The correlations between the clinical data and the concentration of perfluoroalkyl substances were analyzed.

Results. There were 43 male patients and 112 female patients in the cohort. Some of perfluoroalkyl substances (PFOA, PFNA, PFTrA, PFOS) were correlated negatively with the Body Mass Index (BMI); some of them (PFOA, PFNA, PFTrA, PFOS, 8:2Cl-PFESA) were correlated positively with the Disease Activity Score 28 (DAS28); two (PFOA, PFOS) of them were correlated positively with the white blood cell count, and one (PFUnA) of them was correlated negatively with the hemoglobin; two (PFDA, PFUnA) of them were correlated negatively with the presence of interstitial lung disease.

Conclusion. These data suggest that exposure to perfluoroalkyl substances may promote the disease activity of rheumatoid arthritis and the visceral lesions.

Introduction

Rheumatoid arthritis (RA) is one of the classical systemic autoimmune diseases mainly involving joints. The disease affects approximately 0.5-1% of different populations around the world [1]. The pathogenesis of rheumatoid arthritis has not yet been fully elucidated, but the mainstream believes that environmental factors act on individuals with genetic susceptibility to cause immune disorders, leading to the occurrence of joint synovial inflammation and tumor-like proliferation, leading to the destruction of articular cartilage and bone, is the basic mechanism of rheumatoid arthritis. Many genes contribute to increase the susceptibility to rheumatoid arthritis [2], including human leukocyte antigen (HLA) (such as HLA-DRB1) [3] coding genes and non-HLA coding genes (such as PTPN22, PADI4) [4-6]. The current basic research on rheumatoid arthritis is mainly focused on the search for related genetic factors and the characteristics of immune disorders, while the research on environmental factors is relatively less. Some studies showed that smoking and other ways of bronchial damage (e.g., exposure to silica) increase the risk of rheumatoid arthritis among persons with susceptibility HLA-DR4 alleles [7-8]. Environmental factors causing damage to pulmonary and other barrier tissues may promote post-translational modifications, through peptidyl arginine deiminase, type IV (PADI4), that result in citrullination increase of mucosal proteins. Loss of tolerance to such neoepitopes upregulates an ACPA response beyond the endurance range of the body [9-10]. Some other studies showed infectious agents (e.g., Epstein-Barr virus, cytomegalovirus, proteus species, and Escherichia coli) and their components (e.g., heat-shock proteins) were associated with rheumatoid arthritis, and molecular mimicry is postulated [11-12]. Some studies also showed that periodontitis is capable of promoting citrullination of mammalian proteins, thus were associated with RA [13-14]. Finally, intestinal flora dysbiosis and barrier leakage are closely related to the occurrence of rheumatoid arthritis. [15-17].

There is growing concern about the effects of chemical compounds on health. Perfluoroalkyl substances (PFASs), which have been mass-produced and widely used in hundreds of commercial and industrial fields in the past 60 years, are a class of synthetic organic fluorine chemicals with high thermal activity, high chemical stabilities and high surface activity [18]. According to the different polar head group R, PFASs can be divided into different species. Many publications have showed that PFASs could cause a series of health issues. Researchers from the National Health and Nutrition Examination Survey (NHANES) found that most of the participants had measurable PFOS and PFOA concentrations in their bodies [19-20]. Some studies on animal toxicology showed that PFOS could induce some specific genes expressing differentially, thus disturb some functional pathways and cause damage to the cytoskeleton organization and the connections of Sertoli cell-cell [21]. Some studies have reported the link between residual PFOA or PFOS and thyroid disease in humans [22-23]. But the effect of PFASs on autoimmune diseases has not been studied.

In this study, a longitudinal clinical cohort of 155 patients with RA was investigated in Second Affiliated Hospital of Zhejiang University School of Medicine. Serum samples were collected from these participants during the clinic visit and analyzed for PFOA, PFNA, PFDA, PFUnA, PFDoA, PFTrA, PFOS, 8:2Cl-PFESA. The main focus of this study were to explore the association between PFASs in RA patients and the clinic of RA.

Materials And Methods

Patients and Serum collection

We recruited 155 patients with RA in the Zhejiang University School of Medicine Second Affiliated Hospital between March 2019 and Feb 2020. Patients were diagnosed as RA according to the EULAR/ACR 2010 criteria for RA and recruited during a routine rheumatology clinic assessment. There is no evidence that the participants had been occupationally exposure to PFASs. Interstitial lung disease (ILD) was indicated by the presence of fibrosis in computed tomography (CT) scans. Prior to blood sampling, each participant provided a signed informed consent at the time of registration.

Blood sample of participants were collected by physicians or nurses in BD-Vacutainer collection tubes (Becton, Dickinson and Company, NJ, USA) from cubital vein with Anticoagulant. After a brief mixed, the whole blood samples were centrifuged at 3000 r/min for 10 min to separate serum components and transferred to new blood tubes. The separated serum samples that stored in liquid nitrogen tank were then transported to the laboratory. Preparing field blanks (200μL Milli-Q water, n=3) were shipped with real serum samples during the sampling process. All collected serum specimen were stored at -80°C until analysis.

Standards, reagents, and nomenclatures

All Certified standards of br-PFOSK, br-PFHxSK, MPFAC-MXA, PFAC-MXB, 8:2Cl-PFAES, 6:2Cl-PFAES and T-PFOA were obtained from Wellington Laboratories (Guelph, ON, Canada). br-PFOSK, br-PFHxSK and T-PFOA are derivatives of PFOS, PFHxS, PFOA, respectively, which provided by 3 M Co. and based on ¹⁹F-NMR analysis, the relative percentage of linear and branched isomers has precise data. PFAC-MXB consists of various PFAA standard solutions, including PFOA, perfluoropentanoate (PFPeA), perfluorododecanoate (PFDoA), perfluorobutanoate (PFHxA), perfluoroheptanoate (PFHpA), perfluorononanoate (PFNA), perfluoroundecanoate (PFUnA), perfluorobutanoate (PFBA), perfluorohexane sulfonate (PFHxS), perfluorotridecanoate (PFTTrA), perfluorotetradecanoate (PFTTeA), perfluorobutane sulfonate (PFBS), perfluorodecanoate (PFDA), and PFOS. MPFAC-MXA is the mixture of eight isotopically-labeled standards (i.e., ¹³C₄-PFOS, ¹³C₂-PFHxA, ¹³C₅-PFNA, ¹³C₂-PFDA, ¹³C₂-PFUnA, ¹³C₄-PFOA, ¹³C₂-PFDoA, ¹⁸O₂-PFHxS, and ¹³C₂-PFDoA).

Acetonitrile, Methanol (HPLC-grade), formic acid, and ammonium acetate were obtained from J&K Scientific Co.Ltd.(shanghai, China) and ANPEL Laboratory Technologies Inc.(Shanghai, China). Milli-Q water (18 MΩ) was used in the laboratory (Academic A10; Germany).

For PFAS isomers (i.e. PFOA, PFOS, and PFHxS isomers), we adopt the nomenclatures from a previous study. Take PFOA as an example, we are abbreviated the linear, sum of all branched isomers, perfluoroisopropyl, 3-perfluoromethyl, 4-perfluoromethyl, and 5-perfluoromethyl as n-PFOA, br-PFOA, iso-PFOA, 3m-PFOA, 4m-PFOA, and 5m-PFOA, respectively.

Sample extraction

Serum samples were extracted following an acetonitrile-based extraction method [24], with slightly modifications. Prior to extraction, 200μL of serum sample was spiked with internal standards (1.5 ng each), and then shook it by hands until completely mixed. After that, 4 mL acetonitrile were added to the serum samples. The mixture was vortexed, sonicated (53kHz) for 30min, and centrifuged at 4000 r/min for 10min. The supernatant was transferred to a new 10 mL polypropylene (PP) tube (Biosharp, Beijing, China).The above extraction step was repeated once again with 4 mL of Methanol. The eluent was evaporated to near-dryness using gentle nitrogen. The residue was reconstituted in 200 μL of Methanol for HPLC-tandem mass spectrometry (MS/MS) analysis.

Instrumental analysis

Quantification of PFAAs and Cl-PFAESs was carried out using an ultra-performance liquid chromatography system (ACQUITY, UPLC) coupled to a tandem mass spectrometer (XEVO_TQS, MS/MS; Waters Co., Milford, MA, USA) that operated in negative ionization mode. 10 μL of each sample extract was injected onto an ACQUITY UPLC BEH C₁₈ column (1.7 μm, 2.1 mm×50 mm; Waters, Miford, USA) at 40°C. The mobile phase was constituted by 2 mM ammonium acetate (A) and methanol (B). The UPLC flow rate was 0.2 mL/min and the elution gradient started at 80% A and 20% B, then ramped up to 50% B by 12 min and was held at 100% B for 2 min; finally, it was returned to the initial condition. The mass spectrometer was operated in the electrospray negative ionization mode. Recording chromatograms through multiple reaction monitoring. The parent and product ions of target PFASs are listed in Table S1 of the Supporting Information (SI).

Quality Assurance and Quality Control

In order to monitor any method contamination, procedure blanks (i.e., 200μL of Milli-Q water, n=3) and quality control samples was identically performed for the pretreatment of actual human serum samples. When specific PFASs were not detected in the blank samples, limits of detection (LODs) was defined as the addition level corresponding to a signal-to-noise ratio of three. If the analytes that were detected in the blank samples, LODs was reported as the mean value of the concentration plus three times the standard deviation of the blank. Triplicate recovery experiments were performed with spiked samples including human and fetal bovine serum samples. The mean recoveries of main PFASs in human serum were satisfaction, which were in the range of 70-120% and the relative standard deviations (RSD) of recoveries were less than 10%.

Statistical Analysis

Descriptive data are presented as means±standard deviation for continuous variables when the data were normally distributed or as M (P25–P75) when the data were non-normally distributed; numbers (%) are indicated for the categorical variables. Continuous variables were analyzed with Student t test in large samples of similar variance, or with the nonparametric Mann-Whitney U test for small samples. Categorical data were compared using the χ² or Fisher exact tests. A 2-tailed value of P < 0.05 indicated statistical significance. Kruskal-Wallis test was used to compare the variables of multiple groups. Statistical analyses were performed with the 16.0 Stata/MP program (StataCorp LP, College Station, TX).

Results

Demographic, Clinical, and Immunologic Features of 155 Patients With Rheumatoid Arthritis

The patient cohort comprised 155 individuals, including 43 (27.74%) men and 112 (72.26%) women (male: female, ratio, 2.6:1), with a mean age at onset of 45 ± 12 years (range, 24–67 yr). The mean disease duration was 12±2 years (range, 17–21 yr). According to the disease activity assess in rheumatoid arthritis assessed by the number of swelling and tenderness in specific 28 joints, named Disease Activity Score 28 (DAS28-CRP), there were 33 (21.3%) patients with disease inactivity, 44(28.4%) patients with low disease activity, 56 (36.1%) patients with moderate disease activity, and 22 (14.2%) patients with high disease activity. According to the blood routing examination, there were 69 (44.52%) patients with anemia, 12 (7.74%) patients with leucopenia, and no patient with thrombocytopenia. Some patients had mild liver dysfunction and none had kidney dysfunction. There were 143 (92.26%) patients and 118 (76.13%) patients with the disease marker anti-cyclic citrullinated peptide antibody (ACPA) and Rheumatoid Factor (RF) respectively. The detailed data was shown in the Table 1.

TABLE 1. Demographic, Clinical, and Immunologic Features of 155 Chinese Patients With Rheumatoid Arthritis

Variables at protocol*		n = 155
Gender, male, n(%)		43 (27.74)
BMI, mean (S.D.), kg/m ²		22.1± 3.4
Age at onset, mean (S.D.), years		45± 12
Disease duration, mean (S.D.), years		12± 2
DAS28, n(%)	<2.6	33(21.3)
	2.6~3.2	44(28.4)
	3.2~5.1	56(36.1)
	>5.1	22(14.2)
Cytopenia		
Anemia (Hb<110 g/l),n (%)		69(44.52)
Leucopenia (<4×10 ⁹ /L), n (%)		12 (7.74)
Thrombocytopenia (<100×10 ⁹ /L), n (%)		0(0)
Lymphopenia (<0.8×10 ⁹ /L), n (%)		13 (8.39)
High ALT (>50 U/L),n (%)		0(0)
High AST (>35 U/L),n (%)		6(3.87)
High TBL (>21 umol/L),n (%)		0(0)
High ALP (>125 U/L),n (%)		14(9.03)
High GGT (>60 U/L),n (%)		20(12.9)
High Cr (>104 umol/L),n (%)		0(0)
Interstitial Lung Disease, n (%)		27(17.42)
Anti-CCP antibody positive, n (%)		143 (92.26)
RF positive, n (%)		118(76.13)
ILD, n (%)		27(17.4)

Correlation between fluorides and Disease Activity Score 28 of Rheumatoid Arthritis

The disease activity of patients with RA was scored by DAS28-CRP, and the patients were divided into four groups according to DAS28, disease inactivity group (DAS28 < 2.6), low disease activity group (2.6 ≤ DAS28 < 3.2), moderate disease activity group (3.2 ≤ DAS28 < 5.1) and high disease activity group (5.1 ≤ DAS28) respectively. The median serum concentration of PFOA (3.58 ng/mL, 6.00 ng/mL, 12.74 ng/mL, and 19.78 ng/mL), PFNA (1.08 ng/mL, 1.27 ng/mL, 1.35 ng/mL, 1.72 ng/mL), PFOS (2.43 ng/mL, 3.33 ng/mL, 6.01 ng/mL, 6.81 ng/mL) and 8:2Cl-PFESA (0.18 ng/mL, 0.27 ng/mL, 0.42 ng/mL, 0.57 ng/mL) in disease inactivity group, low disease activity group, moderate disease activity group and high disease activity group reached statistical difference with all *p* = 0.0001. But the median serum concentration of PFDA (*p* = 0.0570), PFUnA (*p* = 0.3750), and PFDoA (*p* = 0.6496) was not different statistically in different groups. Although it was different statistically (*p* = 0.0056), the median serum concentration of PFTrA, was 0.14 ng/mL, 0.09 ng/mL, 0.10 ng/mL and 0.12 ng/mL in disease inactivity group, low disease activity group, moderate disease activity group and high disease activity group respectively, did not correlated linearly with the increase of DAS28. The median serum concentration of PFDA, PFUnA and PFDoA did not reach the statistical difference in different DAS28 groups with *p* = 0.0570, *p*= 0.3750 and *p*= 0.6496 respectively. The detailed data was shown in the Table 2.

TABLE 2. Correlation between fluorides and Disease Activity Score 28 of Rheumatoid Arthritis

		PFOA (ng/mL)	PFNA (ng/mL)	PFDA (ng/mL)	PFUnA (ng/mL)	PFDoA (ng/mL)	PFTrA (ng/mL)	PFOS (ng/mL)
DAS28 (M±SD)	<2.6	3.58(2.80~5.05)	1.08(0.58~1.45)	0.77(0.47~1.10)	0.31(0.20~0.45)	0.09(0.08~0.14)	0.14(0.11~0.16)	2.43(1.78~3.09)
	2.6~3.2	6.00(5.01~6.66)	1.27(0.71~2.28)	0.93(0.46~1.32)	0.36(0.26~0.51)	0.09(0.07~0.12)	0.09(0.07~0.12)	3.33(1.83~6.81)
	3.2~5.1	12.74(11.17~14.19)	1.35(0.96~1.79)	1.14(0.67~1.60)	0.41(0.25~0.61)	0.08(0.07~0.14)	0.10(0.08~0.14)	6.01(3.15~11.47)
	≥5.1	19.78(16.70~21.47)	1.72(1.25~2.24)	1.19(0.58~1.90)	0.42(0.27~0.57)	0.09(0.07~0.12)	0.12(0.10~0.15)	6.81(5.19~8.95)
	<i>p</i>	0.0001	0.0001	0.0570	0.3750	0.6496	0.0056	0.0001

Correlation between fluorides and BMI

Fluorides can infect the human beings Body Mass Index (BMI). We investigated the distribution of fluoride concentrations in different BIM groups. The patients were divided into three groups according to BMI, low weight group (BMI < 18.5 Kg/m²), normal weight group (18.5Kg/m² ≤ BMI < 24.9 Kg/m²), and high weight group (BMI ≥ 25 Kg/m²). The median serum concentration of PFOA (14.69 ng/mL, 7.63 ng/mL, 4.01 ng/mL), PFNA (1.70 ng/mL, 1.27 ng/mL, 1.13 ng/mL), and PFOS (5.98 ng/mL, 4.99 ng/mL, 2.78 ng/mL) reached statistical difference in low weight group, normal weight group, and high weight group with *p* = 0.0001, *p* = 0.0007 and *p* = 0.0005 respectively. Although it was different statistically (*p*=0.0225), the median serum concentration of PFTrA, was 0.11 ng/mL, 0.10 ng/mL, and 0.14 ng/mL in low weight group, normal weight group, and high weight group respectively, did not correlated linearly with the BMI. The median serum concentration of PFDA, PFUnA and PFDoA did not reach the statistical difference in different BMI groups with *p* = 0.1149, *p*= 0.3380 and *p*= 0.5405 respectively. The detailed data was shown in the Table 3.

TABLE 3. Correlation between fluoride and BMI

		PFOA	PFNA	PFDA	PFUnA	PFDaA	PFTrA	PFOS
BMI	<18.5	14.69(12.63~19.37)	1.70(1.35~2.31)	0.45(0.50~1.63)	0.38(0.24~0.57)	0.09(0.07~0.14)	0.11(0.08~0.14)	5.98(3.37~7.
	18.5~23.9	7.63(6.25~11.17)	1.27(0.97~2.03)	0.78(0.46~1.13)	0.36(0.20~0.45)	0.09(0.07~0.10)	0.10(0.07~0.14)	4.99(2.17~6.
	≥24	4.01(3.30~6.23)	1.13(0.64~1.52)	0.93(0.51~1.45)	0.41(0.25~0.54)	0.10(0.08~0.16)	0.14(0.10~0.16)	2.78(2.11~3.
	<i>p</i>	0.0001	0.0007	0.1149	0.3380	0.5405	0.0225	0.0005

Correlation between fluorides and hematological damage

We investigated the distribution of fluoride concentrations in different White Blood Cell (WBC) groups and in different hemoglobin (Hb) groups. The patients were divided into two groups according to the count of WBC in blood, leukopenia group (WBC < 4×10⁹/L) and none leukopenia group (WBC ≥ 4×10⁹/L). The median serum concentration of PFOA (10.38 ng/mL, 6.19 ng/mL) and PFOS (5 ng/mL, 2.21 ng/mL) reached statistical difference in leukopenia group and none leukopenia group with *p* = 0.0215 and *p* = 0.0484 respectively. There was no statistically significant difference between the two groups for the remainder fluorides. The detailed data was shown in the Table 4.

We also investigated the distribution of fluoride concentrations in different Hb groups. The patients were divided into two groups according to the concentrations of Hb in blood, hemoglobinopenia group (Hb <100 g/L) and non hemoglobinopenia group (Hb ≥ 100 g/L). The median serum concentration of PFUnA was 0.42 ng/mL and 0.34 ng/mL in hemoglobinopenia group and non hemoglobinopenia group respectively with *p* = 0.0215 and *p* = 0.0484 respectively. There was no statistically significant difference between the two groups for the remainder fluorides. The detailed data was shown in the Table 4.

TABLE 4. Correlation between fluorides and hematological damage

		PFOA	PFNA	PFDA	PFUnA	PFDaA	PFTrA	PFOS
WBC (×10 ⁹ /L)	≥4.0	10.38(5.26~15.29)	1.44(0.87~2.19)	0.91(0.33~1.45)	0.36(0.18~0.52)	0.09(0.07~0.12)	0.11(0.07~0.14)	5(2.17~6.82)
	<4.0	6.19(3.11~7.15)	1.19(0.7~1.67)	0.97(0.53~1.56)	0.35(0.24~0.68)	0.09(0.07~0.13)	0.13(0.07~0.16)	2.21(1.85~3.5
	<i>p</i>	0.0215	0.1390	0.7263	0.9422	0.2833	0.8013	0.0484
Hb (g/L)	≥100	9.44(5.795~15.44)	1.48(1.03~2.14)	0.92(0.46~1.37)	0.34(0.20~0.50)	0.09(0.07~0.12)	0.11(0.08~0.14)	4.50(2.31~6.7
	<100	10.87(6.21~14.94)	1.44(1.11~2.24)	1.03(0.51~1.41)	0.42(0.29~0.54)	0.09(0.07~0.16)	0.11(0.08~0.15)	5.19(2.79~6.6
	<i>p</i>	0.3887	0.4000	0.5663	0.0423	0.5297	0.2555	0.4732

Correlation between fluorides and ILD

Interstitial lung disease (ILD) is one of the most important visceral lesions in patients with RA. The patients were divided into two groups depending on with or without ILD. The study showed the median serum concentration of PFDA and PFUnA was 0.99, 0.51 and 0.38, 0.31 in the none ILD group and ILD group, and the difference was statistically significant with *p* = 0.0173 and *p* = 0.0254. There was no statistically significant difference between the two groups for the remainder fluorides. The detailed data was shown in the Table 5.

TABLE 5. Correlation between fluorides and hematological damage

		PFOA	PFNA	PFDA	PFUnA	PFDaA	PFTrA	PFOS
WBC (×10 ⁹ /L)	≥4.0	10.38(5.26~15.29)	1.44(0.87~2.19)	0.91(0.33~1.45)	0.36(0.18~0.52)	0.09(0.07~0.12)	0.11(0.07~0.14)	5(2.17~6.82)
	<4.0	6.19(3.11~7.15)	1.19(0.7~1.67)	0.97(0.53~1.56)	0.35(0.24~0.68)	0.09(0.07~0.13)	0.13(0.07~0.16)	2.21(1.85~3.5
	<i>p</i>	0.0215	0.1390	0.7263	0.9422	0.2833	0.8013	0.0484
Hb (g/L)	≥100	9.44(5.795~15.44)	1.48(1.03~2.14)	0.92(0.46~1.37)	0.34(0.20~0.50)	0.09(0.07~0.12)	0.11(0.08~0.14)	4.50(2.31~6.7
	<100	10.87(6.21~14.94)	1.44(1.11~2.24)	1.03(0.51~1.41)	0.42(0.29~0.54)	0.09(0.07~0.16)	0.11(0.08~0.15)	5.19(2.79~6.6
	<i>p</i>	0.3887	0.4000	0.5663	0.0423	0.5297	0.2555	0.4732

Discussion

It is considered that environmental factors acting on individuals with genetic susceptibility to cause immune disorders is the basic pathogenesis of initiation of RA. Studies have shown that smoking, alcohol consumption, microbial infection and contraceptives are important environmental factors in the onset of RA. Among them, smoking was the strongest environmental factor associated with RA, and the risk of RA in smokers was 2 to 4 times higher than in non-smokers [25]. The effect of smoking on RA showed a dose-dependent effect, and the longer smoking time, the greater the risk of RA [26]. The risk of RA decreases as the time to quit smoking increases, with abstinence for 15 years reducing the risk by 30 percent compared with abstinence for 1 year [27]. Smoking induces the production of anti-citrullinated Protein antibody (ACPA) in the lungs of RA patients who smoke but not non-smokers [28]. While, alcohol consumption may be a protective factor for RA, and those who consumed 500 grams of white wine per week had a 50 percent lower risk of RA than those who consumed light or no alcohol [29]. Infection, especially viral infection, is also a major environmental factor for RA [30]. Pathogenic microorganisms can both trigger autoimmune responses through molecular mimicry mechanisms and induce citrullination processes, required for the production of ACPA. Recent studies have shown that oral flora, especially periodontal disease caused by *porphyromonas gingivalis*, is closely related to the pathogenesis of RA [31]. Several studies evaluated the role of particulate pollutants in the development of RA, indicating that some particulate pollutants can be treated as antigens by airway epithelial cells and presented to immune cells. Workers exposed to asbestos and silica have a higher risk of RA, suggesting that inorganic dust and CS may play specific roles in inducing disease [32].

Other environmental factors may also influence RA. Fluoride was widely used in production and life at some time ago, and it has been shown to have some effect on human health. Some studies had showed the potential immunomodulatory effects of exposure to Perfluoroalkyl substances (PFASs), and most of them were from studies about associations between exposure to PFASs and vaccine antibody response [33-34]. Some other studies showed that some infectious and allergic diseases correlated with exposure to PFASs [35-36]. So, it is natural to think of a possible association between fluoride and autoimmune diseases, such as RA.

In this study we initially looked at the effect of fluoride on patients with rheumatoid arthritis. We described the demographic, clinical, and Immunologic Features of 155 Chinese Patients With Rheumatoid Arthritis. Most of the patients were female, and the average age of onset was about 43. The average duration of the disease when entering the study was 12 years and most of them had moderate to high disease activity. In the visceral system damage, the most common was the involvement of the blood system, liver and kidney function damage was relatively rare. Interstitial lung disease was not uncommon (table 1).

In this study, we detected 8 fluorides, PFOA, PFNA, PFDA, PFUnA, PFDoA, PFTrA, PFOS, 8:2Cl-PFESA. We found DAS28 related positively with the PFOA, PFNA, PFOS and 8:2Cl-PFESA. We analyzed the relationship between these fluorides and some common clinical indicators of RA. The median serum concentration of PFOA, PFNA, PFOS and 8:2Cl-PFESA in disease inactivity group, low disease activity group, moderate disease activity group and high disease activity group reached statistical difference with all $p = 0.0001$. But the median serum concentration of PFDA ($p = 0.0570$), PFUnA ($p = 0.3750$), and PFDoA ($p = 0.6496$) was not different statistically in different groups. Although it was different statistically ($p = 0.0056$), the median serum concentration of PFTrA did not correlated linearly with the increase of DAS28. The median serum concentration of PFDA, PFUnA and PFDoA did not reach the statistical difference in different DAS28 groups (Table 2). The data showed fluorides may promote the disease activity. The median serum concentration of PFOA, PFNA, and PFOS reached statistical difference in low weight group, normal weight group, and high weight group with $p = 0.0001$, $p = 0.0007$ and $p = 0.0005$ respectively. Although it was different statistically ($p = 0.0225$), the median serum concentration of PFTrA did not correlated linearly with the BMI. The median serum concentration of PFDA, PFUnA and PFDoA did not reach the statistical difference in different BMI groups (Table 3). These data suggest that fluoride may affect nutrient metabolism in RA patients. We also investigated the effects of fluoride on the blood system. The median serum concentration of PFOA and PFOS reached statistical difference in leukopenia group and none leukopenia group with $p = 0.0215$ and $p = 0.0484$ respectively. The median serum concentration of PFUnA reached the statistical difference in hemoglobinopenia group and non hemoglobinopenia group (Table 4). Interstitial lung disease (ILD) is one of the most important visceral lesions in patients with RA. The study showed the median serum concentration of PFDA and PFUnA reached the statistical difference between the none ILD group and ILD group (Table 5). This suggests that fluoride not only affects the disease activity of RA, but may also promote the occurrence of complications, such as blood system abnormality and ILD. In all, the data indicated that there was a strong link between fluorides and RA. However, this study also has great limitations. This study only observed the correlation between fluoride and the clinical manifestations of RA, and further studies are needed to explore the possible mechanism of fluoride promoting the occurrence and development of RA.

Conclusion

In summary, our study showed that perfluoroalkyl substances may be an important environmental factor that promotes the onset and progression of RA.

Abbreviations

PFASs: Perfluoroalkyl substances; RA: Rheumatoid arthritis; PFOA: Perfluorooctanoate; PFNA: Perfluorononanoate; PFTrA: Perfluorotridecanoate; PFOS: Perfluorooctanesulfonate; BMI: Body mass index; 8:2Cl-PFESA: 8:2 Chlorinated polyfluorinated ether sulfonate; DAS28: Disease Activity Score 28; PFUnA: Perfluoroundecanoate; PFDA: Perfluorodecanoate; HLA: Human leukocyte antigen; PTPN22: Protein tyrosine phosphatase non-receptor type 22; PADI4: Peptidylarginine deiminase 4; ACPA: Anti-citrullinated peptide antibodies; NHANES: National Health and Nutrition Examination Survey; EULAR: European League against Rheumatism; ACR: American College of Rheumatology; ILD: Interstitial lung disease; CT: Computed tomography; br-PFOSK: br-Potassium perfluorooctane sulfonate; br-PFHxSK: br-Potassium perfluorohexane sulfonate; PFPeA: perfluoropentanoate; PFDoA: perfluorododecanoate; PFHxA: perfluorobutanoate; PFHpA: perfluoroheptanoate; PFBA: perfluorobutanoate; PFHxS: perfluorohexane sulfonate; PFTeA: perfluorotetradecanoate, PFBS: perfluorobutane sulfonate; HPLC: High performance liquid chromatography; RSD: Relative standard deviations

Declarations

Supplementary Information

The parent and product ions of target PFASs are listed in Table S1 of the Supporting Information (SI).

Acknowledgements

Not applicable.

Authors' contributions

Y.Z., S.Z. and J.X. were responsible for the acquisition of the patient samples and clinical data. H.J., J.Q., S.H. and M.Z. were responsible for the fluoride detection and the acquisition of data. Y.Z., M.Z. and J.X. were responsible for data analysis and interpretation. M.Z. and J.X. were responsible for study conception and design. All authors were involved in drafting the article or revising it critically for important intellectual content. All authors approved the final version to be submitted for publication.

Funding

No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article.

Availability of data and materials

The datasets analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The study was approved by the Ethic Committee of the Zhejiang University School of Medicine Second Affiliated Hospital.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. *Semin Arthritis Rheum* 2006; 36: 182–88.
2. Kurkó J, Besenyei T, Laki J, Glant TT, Mikecz K, Szekanecz Z. Genetics of rheumatoid arthritis - a comprehensive review. *Clin Rev Allergy Immunol*. 2013 Oct;45(2):170-9.
3. Raychaudhuri S, Sandor C, Stahl EA, Freudenberg J *et al*. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. *Nat Genet*. 2012;44:291-6.
4. Bayley R, Kite KA, McGettrick HM *et al*. The autoimmune-associated genetic variant PTPN22 R620W enhances neutrophil activation and function in patients with rheumatoid arthritis and healthy individuals. *Ann Rheum Dis*. 2015 Aug;74(8):1588-95.
5. Massarenti L, Enevold C, Damgaard D *et al*. PADI4 Polymorphisms Confer Risk of Anti-CCP-Positive Rheumatoid Arthritis in Synergy With HLA-DRB1*04 and Smoking. *Front Immunol*. 2021 Oct 18;12:707690.
6. Mustelin T, Bottini N, Stanford SM. The Contribution of PTPN22 to Rheumatic Disease. *Arthritis Rheumatol*. 2019 Apr;71(4):486-495.
7. ISHIKAWA Y, IKARI K, HASHIMOTO M *et al*. Shared epitope defines distinct associations of cigarette smoking with levels of anticitrullinated protein antibody and rheumatoid factor. *Ann Rheum Dis* 2019; 78: 1480-87; 46: 370-75.
8. SEROR R, HENRY J, GUSTO G, AUBIN HJ, BOUTRON-ROUAULT MC, MARIETTE X. Passive smoking in childhood increases the risk of developing rheumatoid arthritis. *Rheumatology (Oxford)* 2019; 58: 1154-62
9. Hensvold AH, Magnusson PKE, Joshua V *et al*. Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation in twins. *Ann Rheum Dis* 2015;74:375–80.
10. Kissel T, van Schie KA, Hafkenscheid L *et al*. On the presence of HLA-SE alleles and ACPA-IgG variable domain glycosylation in the phase preceding the development of rheumatoid arthritis. *Ann Rheum Dis* 2019;78:1616–20.
11. Fadlallah S, Hussein H, Jallad MA *et al*. Effect of Epstein-Barr Virus DNA on the Incidence and Severity of Arthritis in a Rheumatoid Arthritis Mouse Model. *Front Immunol*. 2021 May 10;12:672752. doi: 10.3389/fimmu.2021.672752.
12. Fechtner S, Berens H, Bemis E *et al*. Antibody Responses to Epstein-Barr Virus in the Preclinical Period of Rheumatoid Arthritis Suggest the Presence of Increased Viral Reactivation Cycles. *Arthritis Rheumatol*. 2021 Oct 3. doi: 10.1002/art.41994. Epub ahead of print.

13. Möller B, Kollert F, Sculean A, Villiger PM. Infectious Triggers in Periodontitis and the Gut in Rheumatoid Arthritis (RA): A Complex Story About Association and Causality. *Front Immunol*. 2020 Jun 3;11:1108. doi: 10.3389/fimmu.2020.01108.
14. König MF, Abusleme L, Reinholdt J *et al*. *Aggregatibacter actinomycetemcomitans*-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis. *Sci Transl Med*. 2016 Dec 14;8(369):369ra176.
15. KIM D, KIM W U. Editorial: Can *Prevotella copri* be a causative pathobiont in rheumatoid arthritis? [J]. *Arthritis Rheumatol*, 2016,68(11):2565-2567.
16. ZHANG X, ZHANG D, JIA H *et al*. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment[J]. *Nat Med*, 2015,21(8):895-905.
17. TENG F, KLINGER C N, FELIX K M *et al*. Gut microbiota drive autoimmune arthritis by promoting differentiation and migration of peyer's patch T follicular helper cells [J]. *Immunity*, 2016,44 (4):875-888.
18. Lindstrom AB, Strynar MJ, Libelo EL. 2011. Polyfluorinated compounds: Past, present, and future. *Environ Sci Technol* 45:7954-7961.
19. Calafat AM, Wong LY, Kuklenyik Z, Reidy JA, Needham LL. Polyfluoroalkyl chemicals in the u.S. Population: Data from the national health and nutrition examination survey (nhanes) 2003-2004 and comparisons with nhanes 1999-2000. *Environ Health Perspect*, 2007,115:1596-1602.
20. Zhang H, Lu Y, Luo B, Yan S, Guo X, Dai J. Proteomic analysis of mouse testis reveals perfluorooctanoic acid-induced reproductive dysfunction via direct disturbance of testicular steroidogenic machinery. *J Proteome Res*, 2014, 13:3370-3385.
21. Wan HT, Lai KP, Wong CKC. Comparative analysis of pfos and pfoa toxicity on sertoli cells. *Environ Sci Technol*, 2020, 54:3465-3475.
22. Melzer D, Rice N, Depledge MH, Henley WE, Galloway TS. Association between serum perfluorooctanoic acid (pfoa) and thyroid disease in the u.S. National health and nutrition examination survey. *Environ Health Perspect*, 2010, 118:686-692.
23. Webster GM, Venners SA, Mattman A, Martin JW. Associations between perfluoroalkyl acids (pfass) and maternal thyroid hormones in early pregnancy: A population-based cohort study. *Environ Res*, 2014, 133:338-347.
24. Jin H, Zhang Y, Jiang W, Zhu L, Martin JW. Isomer-specific distribution of perfluoroalkyl substances in blood. *Environ Sci Technol*, 2016, 50:7808-7815.
25. Sugiyama D, Nishimura K, Tamaki K *et al*. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. *Ann Rheum Dis*. 2010 Jan;69(1):70-81.
26. Di Giuseppe D, Orsini N, Alfredsson L, Askling J, Wolk A. Cigarette smoking and smoking cessation in relation to risk of rheumatoid arthritis in women. *Arthritis Res Ther*. 2013 Apr 22;15(2):R56.
27. Klareskog L, Stolt P, Lundberg K *et al*. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. *Arthritis Rheum*. 2006 Jan;54(1):38-46.
28. Saevardottir S, Wedrén S, Seddighzadeh M *et al*. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. *Arthritis Rheum*. 2011 Jan;63(1):26-36.
29. Källberg H, Jacobsen S, Bengtsson C *et al*. Alcohol consumption is associated with decreased risk of rheumatoid arthritis: results from two Scandinavian case-control studies. *Ann Rheum Dis*. 2009 Feb;68(2):222-7.
30. JOO YB, LIM YH, KIM KJ, PARK KS, PARK YJ. Respiratory viral infections and the risk of rheumatoid arthritis. *Arthritis Res Ther* 2019; 21: 199.
31. ALPIZAR-RODRIGUEZ D, LESKER TR, GRONOW A *et al*. *Prevotella copri* in individuals at risk for rheumatoid arthritis. *Ann Rheum Dis* 2019; 78: 590-93.
32. Ilar A, Gustavsson P, Wiebert P, Alfredsson L. Occupational exposure to organic dusts and risk of developing rheumatoid arthritis: findings from a Swedish population-based case-control study. *RMD Open*. 2019 Nov 21;5(2):e001049.
33. Stein CR, McGovern KJ, Pajak AM, Maglione PJ, Wolff MS. Perfluoroalkyl and polyfluoroalkyl substances and indicators of immune function in children aged 12-19 y: National Health and Nutrition Examination Survey. *Pediatr Res*. 2016 Feb;79(2):348-57.
34. Grandjean P, Andersen EW, Budtz-Jørgensen E *et al*. Serum vaccine antibody concentrations in children exposed to perfluorinated compounds. *JAMA*. 2012 Jan 25;307(4):391-7.
35. Goudarzi H, Miyashita C, Okada E *et al*. Prenatal exposure to perfluoroalkyl acids and prevalence of infectious diseases up to 4 years of age. *Environ Int*. 2017 Jul;104:132-138. Smit LA, Lenters V, Høyer BB *et al*. Prenatal exposure to environmental chemical contaminants and asthma and eczema in school-age children. *Allergy*. 2015 Jun;70(6):653-60.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [TABLEsupp.docx](#)